Literature DB >> 4074823

Confidence limits for probability of response in multistage phase II clinical trials.

E N Atkinson, B W Brown.   

Abstract

Herson (1979, Biometrics 35, 775-783) has given a method for designing one-arm k-stage phase II clinical trials, which permits early termination of the trial if the treatment is apparently ineffective, while retaining acceptable levels of power and significance. This paper gives a method for calculating the confidence limits on the response proportion, conditional on a particular study design.

Mesh：

Year:  1985        PMID： 4074823

Source DB:  PubMed          Journal:  Biometrics        ISSN： 0006-341X            Impact factor:   2.571


  31 in total

1.  Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B.

Authors:  N J Vogelzang; M Goutsou; J M Corson; Y Suzuki; S Graziano; J Aisner; M R Cooper; K M Coughlin; M R Green
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer.

Authors:  Atish D Choudhury; Kathryn P Gray; Jeffrey G Supko; Lauren C Harshman; Mary-Ellen Taplin; Amanda F Pace; Matthew Farina; Katherine A Zukotynski; Brandon Bernard; Philip W Kantoff; Mark Pomerantz; Christopher Sweeney
Journal:  Prostate       Date:  2018-06-07       Impact factor: 4.104

3.  Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).

Authors:  Julie E Chang; Hailun Li; Mitchell R Smith; Randy D Gascoyne; Elisabeth M Paietta; David T Yang; Ranjana H Advani; Sandra J Horning; Brad S Kahl
Journal:  Blood       Date:  2014-01-23       Impact factor: 22.113

4.  Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.

Authors:  Gini F Fleming; Virginia L Filiaci; Brandon Marzullo; Richard J Zaino; Susan A Davidson; Michael Pearl; Vicky Makker; James J Burke; Susan L Zweizig; Linda Van Le; Parviz Hanjani; Gordon Downey; Joan L Walker; Henry D Reyes; Kimberly K Leslie
Journal:  Gynecol Oncol       Date:  2014-01-20       Impact factor: 5.482

5.  Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293.

Authors:  A I Einzig; D Neuberg; S C Remick; D D Karp; P J O'Dwyer; J A Stewart; A B Benson
Journal:  Med Oncol       Date:  1996-06       Impact factor: 3.064

6.  Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study.

Authors:  Matthew A Powell; Virginia L Filiaci; Peter G Rose; Robert S Mannel; Parviz Hanjani; Koen Degeest; Brigitte E Miller; Nobuyuki Susumu; Frederick R Ueland
Journal:  J Clin Oncol       Date:  2010-04-26       Impact factor: 44.544

7.  E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer.

Authors:  Taofeek K Owonikoko; Joseph Aisner; Xin Victoria Wang; Suzanne E Dahlberg; Eric H Rubin; Suresh S Ramalingam; Murugesan Gounder; Paul Gregory Rausch; Rita S Axelrod; Joan H Schiller
Journal:  Cancer Chemother Pharmacol       Date:  2013-11-28       Impact factor: 3.333

8.  Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Randomized Phase 2 Trial of Neoadjuvant Preoperative Paclitaxel/Cisplatin/Radiation Therapy (RT) or Irinotecan/Cisplatin/RT in Esophageal Adenocarcinoma: Long-Term Outcome and Implications for Trial Design.

Authors:  Lawrence R Kleinberg; Paul J Catalano; Arlene A Forastiere; Steven M Keller; Edith P Mitchel; Pramila Rani Anne; Al B Benson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-12-18       Impact factor: 7.038

9.  A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia.

Authors:  Janice P Dutcher; Evelyn L Morris; Bruce Gaynor; Elisabeth Paietta; Peter H Wiernik
Journal:  Med Oncol       Date:  2009-08-21       Impact factor: 3.064

10.  Second Curettage for Low-Risk Nonmetastatic Gestational Trophoblastic Neoplasia.

Authors:  Raymond J Osborne; Virginia L Filiaci; Julian C Schink; Robert S Mannel; Kian Behbakht; James S Hoffman; Nick M Spirtos; John K Chan; John A Tidy; David S Miller
Journal:  Obstet Gynecol       Date:  2016-09       Impact factor: 7.661
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.